{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:29:48Z","timestamp":1791415788835,"version":"4.3.3"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800480"],"award-info":[{"award-number":["81800480"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["822706142"],"award-info":[{"award-number":["822706142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8177058"],"award-info":[{"award-number":["8177058"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.lfs.2024.123095","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T11:45:50Z","timestamp":1727955950000},"page":"123095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Rifaximin alleviates MCD diet-induced NASH in mice by restoring the gut microbiota and intestinal barrier"],"prefix":"10.1016","volume":"357","author":[{"given":"Yan Yun","family":"SHU","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Lin","family":"HU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"YE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"YANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"JIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.lfs.2024.123095_bb0005","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.metabol.2015.11.008","article-title":"Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"65","author":"Brown","year":"2016","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.lfs.2024.123095_bb0010","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jhep.2015.02.005","article-title":"Non-alcoholic fatty liver - perhaps not so benign","volume":"62","author":"Adams","year":"2015","journal-title":"J. Hepatol."},{"issue":"suppl","key":"10.1016\/j.lfs.2024.123095_bb0015","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","article-title":"Non-alcoholic fatty liver disease: definition and subtypes","volume":"29","author":"Han","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"7","key":"10.1016\/j.lfs.2024.123095_bb0020","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1007\/s12325-019-00960-3","article-title":"A structured literature review of the epidemiology and disease burden of non-alcoholic steatohepatitis (NASH)","volume":"36","author":"Povsic","year":"2019","journal-title":"Adv. Ther."},{"issue":"47","key":"10.1016\/j.lfs.2024.123095_bb0025","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","article-title":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease","volume":"23","author":"Perumpail","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.lfs.2024.123095_bb0030","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1055\/a-0784-8827","article-title":"Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments","volume":"57","author":"Roeb","year":"2019","journal-title":"Z. Gastroenterol."},{"issue":"9","key":"10.1016\/j.lfs.2024.123095_bb0035","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","article-title":"Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options","volume":"119","author":"Grander","year":"2023","journal-title":"Cardiovasc. Res."},{"issue":"9","key":"10.1016\/j.lfs.2024.123095_bb0040","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/ja.2014.106","article-title":"Rifaximin: beyond the traditional antibiotic activity","volume":"67","author":"Calanni","year":"2014","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"2","key":"10.1016\/j.lfs.2024.123095_bb0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/jgh.13841","article-title":"Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota","volume":"33","author":"Jin","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.lfs.2024.123095_bb0050","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/MEG.0000000000000348","article-title":"Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease","volume":"27","author":"Gangarapu","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.lfs.2024.123095_bb0055","doi-asserted-by":"crossref","first-page":"732","DOI":"10.36740\/WLek202404118","article-title":"Effectiveness of rifaximin and probiotics for the correction of intestinal permeability in patients with metabolic-associated fatty liver disease in combination with type 2 diabetes mellitus","volume":"77","author":"Didyk","year":"2024","journal-title":"Wiad. Lek."},{"key":"10.1016\/j.lfs.2024.123095_bb0060","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809302","article-title":"The role of the microbiome in NAFLD and NASH","author":"Kolodziejczyk","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.lfs.2024.123095_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.997018","article-title":"Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications","volume":"12","author":"Fang","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"2","key":"10.1016\/j.lfs.2024.123095_bb0070","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.lfs.2024.123095_bb0075","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"Mouries","year":"2019","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.lfs.2024.123095_bb0080","doi-asserted-by":"crossref","DOI":"10.1111\/asj.13357","article-title":"Regulation of the intestinal barrier by nutrients: the role of tight junctions","volume":"91","author":"Suzuki","year":"2020","journal-title":"Anim. Sci. J."},{"issue":"11","key":"10.1016\/j.lfs.2024.123095_bb0085","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nri2653","article-title":"Intestinal mucosal barrier function in health and disease","volume":"9","author":"Turner","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.lfs.2024.123095_bb0090","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hep.31056","article-title":"Increased liver localization of lipopolysaccharides in human and experimental NAFLD","volume":"72","author":"Carpino","year":"2020","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.lfs.2024.123095_bb0095","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.lfs.2024.123095_bb0100","doi-asserted-by":"crossref","first-page":"548","DOI":"10.2174\/156802612799436669","article-title":"Biology and therapeutic applications of peroxisome proliferator- activated receptors","volume":"12","author":"Menendez-Gutierrez","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.lfs.2024.123095_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2024.123095_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10010084","article-title":"Bifidobacterium bifidum shows more diversified ways of relieving non-alcoholic fatty liver compared with Bifidobacterium adolescentis","author":"Wang","year":"2021","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.lfs.2024.123095_bb0115","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/apt.15416","article-title":"Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease","volume":"50","author":"Koopman","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.lfs.2024.123095_bb0120","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s42255-020-0261-2","article-title":"Fructose stimulated de novo lipogenesis is promoted by inflammation","volume":"2","author":"Todoric","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.lfs.2024.123095_bb0125","article-title":"New insights into the pathogenesis of non-alcoholic fatty liver disease: gut-derived lipopolysaccharides and oxidative stress","volume":"12(9).doi:10.3390\/nu12092762","author":"Ferro","year":"2020","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.lfs.2024.123095_bb0130","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/hep.30333","article-title":"Mouse models of nonalcoholic steatohepatitis: toward optimization of their relevance to human nonalcoholic steatohepatitis","volume":"69","author":"Farrell","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.lfs.2024.123095_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0032-1306421","article-title":"Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research","volume":"32","author":"Kleiner","year":"2012","journal-title":"Semin. Liver Dis."},{"issue":"3","key":"10.1016\/j.lfs.2024.123095_bb0140","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.lfs.2024.123095_bb0145","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1586\/1744666X.2014.979792","article-title":"Diagnosis and management of primary biliary cirrhosis","volume":"10","author":"Ali","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.lfs.2024.123095_bb0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nmeth.f.303","article-title":"QIIME allows analysis of high-throughput community sequencing data","volume":"7","author":"Caporaso","year":"2010","journal-title":"Nat. Methods"},{"key":"10.1016\/j.lfs.2024.123095_bb0155","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/107434","article-title":"Misregulation of PPAR functioning and its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesity","volume":"2012","author":"Videla","year":"2012","journal-title":"PPAR Res."},{"issue":"2","key":"10.1016\/j.lfs.2024.123095_bb0160","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ajpath.2011.10.025","article-title":"Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function","volume":"180","author":"Patel","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.lfs.2024.123095_bb0165","doi-asserted-by":"crossref","first-page":"E334","DOI":"10.1152\/ajpendo.00107.2017","article-title":"Reduced obesity, diabetes, and steatosis upon cinnamon and grape pomace are associated with changes in gut microbiota and markers of gut barrier","volume":"314","author":"Van Hul","year":"2018","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"23","key":"10.1016\/j.lfs.2024.123095_bb0170","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.3748\/wjg.v20.i23.7381","article-title":"Role of gut microbiota and toll-like receptors in nonalcoholic fatty liver disease","volume":"20","author":"Miura","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.lfs.2024.123095_bb0175","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nri3608","article-title":"Intestinal epithelial cells: regulators of barrier function and immune homeostasis","volume":"14","author":"Peterson","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.lfs.2024.123095_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrgastro.2016.169","article-title":"The intestinal epithelial barrier: a therapeutic target?","volume":"14","author":"Odenwald","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.lfs.2024.123095_bb0185","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jcmgh.2015.01.001","article-title":"Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability","volume":"1","author":"Luther","year":"2015","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2024.123095_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108391","article-title":"PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: pathogenesis and therapeutic targets","volume":"245","author":"Chen","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2024.123095_bb0195","first-page":"0276","article-title":"Herpetrione, a new type of PPAR\u03b1 ligand as a therapeutic strategy against nonalcoholic steatohepatitis","volume":"6","author":"Linghu","year":"2023","journal-title":"Research (Wash D C)."},{"issue":"1","key":"10.1016\/j.lfs.2024.123095_bb0200","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7150\/ijbs.87305","article-title":"The role of nuclear receptors in the pathogenesis and treatment of non-alcoholic fatty liver disease","volume":"20","author":"Yang","year":"2024","journal-title":"Int. J. Biol. Sci."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524006854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524006854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:18:14Z","timestamp":1778638694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320524006854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":40,"alternative-id":["S0024320524006854"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123095","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rifaximin alleviates MCD diet-induced NASH in mice by restoring the gut microbiota and intestinal barrier","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123095"}}